ClinicalTrials.gg
CompletedNCT03898180Updated Feb 5, 2026Results posted

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

A Phase 3 interventional study of Pembrolizumab and Lenvatinib in Urothelial Carcinoma, sponsored by Merck Sharp & Dohme LLC. Completed at 194 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
505
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 360 studies in Carcinoma, Transitional Cell with a site in United States — 77 open to participants now, 140 under way, 14 of them phase 3. Carcinoma, Transitional Cell · United States.

Enrollment
25th of 333
505 · median 46
Started
2019
with 40 others
Phase 3
25 of 360
5 open now
Registered
178th of 360
by date

Among the 360 studies in Carcinoma, Transitional Cell with a site in United States, this one is the 25th largest by enrollment of the 333 interventional ones that give a count, is one of 41 that started in 2019, is one of 25 in phase 3, and was the 178th registered.

Carcinoma, Transitional Cell

632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

77 of the 360 studies in Carcinoma, Transitional Cell with a site in United States are open now. Recruiting first, the newest first:

72 more — sign in →

All 77 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 360 studies in Carcinoma, Transitional Cell with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of lenvatinib (MK-7902/E7080) in combination with pembrolizumab (MK-3475) in the treatment of cisplatin-ineligible participants with a Programmed Cell Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10, or in participants ineligible for any platinum-containing chemotherapy regardless of CPS, with advanced/unresectable or metastatic urothelial carcinoma (UC).

The primary hypotheses for this study are that:

  1. Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR), and
  2. Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Overall Survival (OS).

Based on recommendation of the external Data Monitoring Committee (eDMC), Amendment 3 (effective: September [Sep]-24-2021) was implemented to unblind the study and discontinue lenvatinib and placebo treatment. The eDMC was then disbanded.

With Amendment 4 (effective: December-5-2022) second course pembrolizumab will no longer be offered. Any participant receiving second course pembrolizumab treatment prior to initiation of Amendment 4 will be able to complete treatment as planned. Study participation will end after the final administration of pembrolizumab. Participants who either complete 35 administrations of pembrolizumab or discontinue pembrolizumab will discontinue from the study following the safety follow-up visit. AEs and spontaneously reported pregnancies will be reported and followed per protocol. The overall study ends when the last participant completes the last study-related contact or visit, withdraws from the study, or is lost to follow-up.

03

Conditions studied

  • Urothelial Carcinoma

Keywords

  • Advanced or metastatic urothelial cancer
  • Lenvatinib
  • Pembrolizumab
  • Programmed Cell Death-1 (PD1, PD-1)
  • Programmed Cell Death 1 Ligand 1 (PDL1, PD-L1)
  • Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a or cytologically confirmed diagnosis of advanced/unresectable (inoperable) or urothelial carcinoma (UC) of the renal pelvis, ureter (upper urinary tract), bladder, or urethra.
  • Has ≥1 measurable target lesion per 1.1 as assessed by the local site investigator/radiologist.
  • Has provided an sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated and adequate for Programmed Death-Ligand 1 () evaluation.
  • Has received no prior systemic chemotherapy for advanced or metastatic UC with the following exceptions:
  • (prior to surgery) platinum-based chemotherapy for treatment of muscle-invasive bladder cancer with recurrence >12 months from completion of the therapy is permitted.
  • Adjuvant (following surgery) platinum-based chemotherapy following radical cystectomy, with recurrence >12 months from completion of the therapy, is permitted.
  • Meets criteria for either option a or option b (below):
  • a. Has a tumor(s) with PD-L1 combined positive score (CPS) ≥10 and is considered ineligible to receive cisplatin-based combination therapy, based on 1 of the following:
  • (ECOG) performance status (PS) score of 2 within 7 days prior to randomization
  • National Cancer Institute (NCI) (CTCAE) Version 4.0 Grade ≥2 audiometric hearing loss
  • NCI CTCAE Version 4.0 Grade ≥2 peripheral neuropathy OR
  • b. In the opinion of the investigator, is considered ineligible to receive any platinum-based chemotherapy (i.e., ineligible for cisplatin and carboplatin) based on:
  • ECOG PS of 2 within 7 days prior to randomization and ≥1 of the following:
  • Documented visceral metastatic disease
  • NCI CTCAE Version 4.0 Grade ≥2 audiometric hearing loss
  • NCI CTCAE Version 4.0 Grade ≥2 peripheral neuropathy
  • Other reason for the participant's being unable to receive both cisplatin and carboplatin safely. Additional criteria for platinum ineligibility will be considered and allowed on a case-by-case basis, following consultation with the Sponsor. Note: Participants considered ineligible for any platinum-based chemotherapy are eligible for this study regardless of their tumor PD-L1 status.
  • Has ECOG PS 0, 1, or 2 within 7 days prior to randomization and a of ≥3 months.
  • Male participants are eligible to participate if they agree to the following during the treatment period and for ≥30 days after the last dose of pembrolizumab or lenvatinib/placebo:
  • Be abstinent from heterosexual intercourse as their preferred and usual lifestyle and agree to remain abstinent, OR
  • Must agree to use unless confirmed to be azoospermic (vasectomized or secondary to medical cause as detailed below:
  • Agrees to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a woman of (WOCBP) who is not currently pregnant. Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile-vaginal penetration.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding and if she is not a WOCBP OR is a WOCBP and is using a contraceptive method that is highly effective (with a failure rate of \<1% per year) with low user dependency, or is abstinent from heterosexual intercourse as her preferred and usual lifestyle during the intervention period and for ≥120 days post pembrolizumab or ≥30 days post lenvatinib/placebo.
  • Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤150/90 mm Hg at screening and no change in antihypertensive medications within 1 week prior to randomization.
  • Has adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Has disease that is suitable for local therapy administered with curative intent (e.g. chemotherapy and radiation for Stage 3 disease).
  • Has tumor with any neuroendocrine or small cell component.
  • Has a history of a gastrointestinal condition or procedure (e.g. gastric bypass, malabsorption) that, in the opinion of the investigator, may affect oral drug absorption.
  • Has had major surgery within 3 weeks prior to the first dose of study treatment
  • Has a pre-existing Grade ≥3 gastrointestinal or non-gastrointestinal fistula.
  • Has radiographic evidence of major blood vessel invasion/infiltration, or has had hemoptysis (≥0.5 teaspoon of bright red blood) or tumor bleeding within 2 weeks prior to the first dose of study treatment.
  • Has had significant cardiovascular impairment within 12 months of the first dose of study treatment, such as history of (NYHA) >Class II congestive heart failure, unstable angina, myocardial infarction or cerebrovascular accident (CVA)/stroke, cardiac revascularization procedure, or cardiac arrhythmia associated with hemodynamic instability.
  • Has known intolerance or severe (Grade ≥3) to pembrolizumab or lenvatinib or any of their
  • Has received lenvatinib as monotherapy or in combination with a programmed cell death-1/programmed cell death-ligand 1 (/PD-L1) inhibitor or has previously been enrolled in a clinical study evaluating lenvatinib for bladder cancer, regardless of the treatment received.
  • Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 inhibitor, indoleamine-pyrrole 2,3 dioxygenase (IDO1) inhibitor, or agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4], OX 40, CD137), or any other antibody or drug targeting T-cell costimulatory pathways in the or advanced/ setting.
  • Has received prior radiotherapy to a metastatic site without the use of chemotherapy radiosensitization within 3 weeks of the first dose of study treatment, with the exception of palliative radiotherapy to bone lesions, which is allowed if completed 2 weeks before the start of study treatment. Participants must have recovered from all radiation-related toxicities, and must not require .
  • Has received a within 30 days prior to the first dose of study treatment.
  • In the investigator's judgment, has not recovered from toxicity or other complications from any major surgery prior to starting study treatment.
  • Is currently participating in or has participated in a study of an agent or has used an investigational device within 4 weeks prior to the first dose of study treatment. Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.
  • Has history or presence of an abnormal (ECG) that, in the investigator's opinion, is clinically meaningful.
  • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (at a dose exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to randomization.
  • Has had an active (except locally advanced or metastatic UC) within the past 36 months. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) who have undergone potentially curative therapy are not excluded.
  • Has a history of prostate cancer (T2NXMX or lower with Gleason score ≤7) treated with definitive intent (surgically or with radiation therapy) ≥1 year prior to study entry is acceptable, provided that the participant is considered prostate cancer-free.
  • Has central nervous system (CNS) metastases, unless the participant has completed local therapy (e.g. whole brain radiation therapy, surgery, or radiosurgery) and has discontinued use of corticosteroids for this indication for ≥4 weeks before starting study treatment. Any signs (e.g. radiologic) or symptoms of must be stable for ≥4 weeks before starting study treatment.
  • Has an active disease that has required systemic treatment in the past 2 years (i.e., with disease-modifying agents, corticosteroids, or immunosuppressive drugs).
  • Has a history of (non-infectious) pneumonitis that required systemic steroids, or current pneumonitis.
  • Has an active infection requiring systemic therapy.
  • Has a known history of (HIV) infection.
  • Has a known history of or is positive for active virus (HBV) or has active virus (HCV).
  • Has active tuberculosis (TB).
  • Is receiving hemodialysis.
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of pembrolizumab and lenvatinib/placebo.
  • Has had an allogeneic tissue/solid organ transplant.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
505 participants (actual)

Study arms

  • Experimental
    Pembrolizumab + Lenvatinib

    Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to \~2 years) PLUS lenvatinib 20 mg via oral capsule once daily (QD) until progressive disease or discontinuation. With protocol amendment 3 (effective: Sep-24-2021), participants discontinue lenvatinib.

    Biological: Pembrolizumab · Drug: Lenvatinib

  • Active comparator
    Pembrolizumab + Placebo

    Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to \~2 years) PLUS placebo for lenvatinib via oral capsule QD until progressive disease or discontinuation. With protocol amendment 3 (effective: Sep-24-2021), participants discontinue placebo.

    Biological: Pembrolizumab · Drug: Placebo for lenvatinib

Interventions

  • BiologicalPembrolizumab

    IV infusion

    Also known as: MK-3475, KEYTRUDA®

  • oral capsule

    Also known as: MK-7902, E7080, LENVIMA®

  • DrugPlacebo for lenvatinib

    oral capsule

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    PFS was defined as the time from randomization to the first documented PD per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR), or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS as assessed by BICR per RECIST 1.1 is presented. Protocol-specified final analysis for this primary outcome measure was performed with an analysis data cut-off date of Jul-26-2021.

    Time frame: Up to approximately 25 months

  2. Overall Survival (OS)

    OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were to be censored at the date of the last follow-up. Protocol-specified final analysis for this primary outcome measure was performed with an analysis data cut-off date of Jul-26-2021.

    Time frame: Up to approximately 25 months

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants who had a confirmed CR (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by BICR. The percentage of participants who experienced a CR or PR is presented. Protocol-specified final analysis for this secondary outcome measure was performed with an analysis data cut-off date of Jul-26-2021.

    Time frame: Up to approximately 25 months

  2. Duration of Response (DOR)

    For participants who demonstrated a confirmed CR (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by BICR, DOR was defined as the time from first documented evidence of a CR or PR until PD or death. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions as well as an absolute increase of ≥5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. The DOR as assessed by BICR per RECIST 1.1 for participants who experienced a confirmed CR or PR is presented. Protocol-specified final analysis for this secondary outcome measure was performed with an analysis data cut-off date of Jul-26-2021.

    Time frame: Up to approximately 25 months

  3. Disease Control Rate (DCR)

    DCR was defined as the percentage of participants who have a CR (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) or stable disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD \[PD: ≥20% increase in the sum of diameters of target lesions and an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD\]). DCR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. The DCR as assessed by BICR per RECIST 1.1 is presented. Protocol-specified final analysis for this secondary outcome measure was performed with an analysis data cut-off date of Jul-26-2021.

    Time frame: Up to approximately 25 months

  4. Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS) (Item 29) and Quality of Life (QOL) (Item 30) Combined Score

    The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions regarding GHS ("How would you rate your overall health during the past week?") and QOL ("How would you rate your overall quality of life during the past week?") were scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores were standardized, so that scores range from 0 to 100. The change from baseline in GHS (EORTC QLQ-C30 Item 29) and QOL (EORTC QLQ-C30 Item 30) combined score is presented. A higher score indicates a better outcome. Final analysis for this secondary outcome measure was performed with an analysis data cut-off date of Jul-26-2021, as specified in the Supplemental Statistical Analysis Plan (sSAP).

    Time frame: Baseline and Week 11

  5. Time to True Deterioration (TTD) Based on Change From Baseline in EORTC QLQ-C30 GHS (Item 29) and QOL (Item 30) Combined Score

    TTD was defined as the time from baseline to the first onset of a ≥10-point negative change (decrease) from baseline in GHS (EORTC QLQ-C30 Item 29) \& QOL (EORTC QLQ-C30 Item 30) combined score. The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions regarding GHS ("How would you rate your overall health during the past week?") and QOL ("How would you rate your overall quality of life during the past week?") were scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores were standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from baseline in GHS and QOL combined score, is presented. A longer TTD indicates a better outcome. Final analysis for this secondary outcome measure was performed with an analysis data cut-off date of Jul-26-2021, as specified in the sSAP.

    Time frame: Baseline and up to approximately 25 months

  6. Number of Participants Who Experience an AE

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE is presented. Final analysis for this secondary outcome measure was performed with an analysis data cut-off date of Jul-26-2021.

    Time frame: Up to approximately 25 months

  7. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE is presented. Final analysis for this secondary outcome measure was performed with an analysis data cut-off date of Jul-26-2021.

    Time frame: Up to approximately 25 months

07

Results

Posted Oct 31, 2023

Participant flow

Participant flow — Overall Study
MilestonePembrolizumab + LenvatinibPembrolizumab + Placebo
Started251254
Treated247254
Pembrolizumab + lenvatinib vs. pembrolizumab + placebo efficacy analyses245242
Pembrolizumab + lenvatinib vs. pembrolizumab + placebo safety analyses241242
Received second course of pembrolizumab25
Completed6377
Not completed188177
Withdrew: Death178173
Withdrew: Physician decision10
Withdrew: Sponsor decision30
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject54

Outcome measures

PrimaryProgression-free Survival (PFS)

PFS was defined as the time from randomization to the first documented PD per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR), or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS as assessed by BICR per RECIST 1.1 is presented. Protocol-specified final analysis for this primary outcome measure was performed with an analysis data cut-off date of Jul-26-2021.

Time frame:
Up to approximately 25 months
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsPembrolizumab + LenvatinibPembrolizumab + Placebo
Progression-free Survival (PFS)4.5 (4.0 to 6.0)4.0 (2.7 to 5.4)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · Log Rank · p = 0.4107 (Two-sided p-value based on log rank test stratified on chemotherapy ineligibility, programmed cell death ligand 1 (PD-L1) CPS, and ECOG performance status (PS).) · Hazard ratio (hr): 0.90 · 95% CI 0.72 to 1.14Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified on chemotherapy ineligibility, PD-L1 CPS, and ECOG PS.
PrimaryOverall Survival (OS)

OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were to be censored at the date of the last follow-up. Protocol-specified final analysis for this primary outcome measure was performed with an analysis data cut-off date of Jul-26-2021.

Time frame:
Up to approximately 25 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsPembrolizumab + LenvatinibPembrolizumab + Placebo
Overall Survival (OS)11.8 (9.1 to 15.1)12.9 (9.8 to 17.8)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · Log Rank · p = 0.3505 (Two-sided p-value based on log rank test stratified on chemotherapy ineligibility, PD-L1 CPS, and ECOG PS.) · Hazard ratio (hr): 1.14 · 95% CI 0.87 to 1.48Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified on chemotherapy ineligibility, PD-L1 CPS, and ECOG PS.
SecondaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants who had a confirmed CR (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by BICR. The percentage of participants who experienced a CR or PR is presented. Protocol-specified final analysis for this secondary outcome measure was performed with an analysis data cut-off date of Jul-26-2021.

Time frame:
Up to approximately 25 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR)
Percentage of ParticipantsPembrolizumab + LenvatinibPembrolizumab + Placebo
Objective Response Rate (ORR)33.1 (27.2 to 39.3)28.9 (23.3 to 35.1)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · Difference in percentage: 4.1 · 95% CI -4.0 to 12.2Based on Miettinen \& Nurminen method stratified on chemotherapy ineligibility, PD-L1 CPS, and ECOG PS.
SecondaryDuration of Response (DOR)

For participants who demonstrated a confirmed CR (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by BICR, DOR was defined as the time from first documented evidence of a CR or PR until PD or death. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions as well as an absolute increase of ≥5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. The DOR as assessed by BICR per RECIST 1.1 for participants who experienced a confirmed CR or PR is presented. Protocol-specified final analysis for this secondary outcome measure was performed with an analysis data cut-off date of Jul-26-2021.

Time frame:
Up to approximately 25 months
Reported as:
Median · Months
Duration of Response (DOR)
MonthsPembrolizumab + LenvatinibPembrolizumab + Placebo
Duration of Response (DOR)NA (NA to NA)NA (NA to NA)
SecondaryDisease Control Rate (DCR)

DCR was defined as the percentage of participants who have a CR (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) or stable disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD \[PD: ≥20% increase in the sum of diameters of target lesions and an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD\]). DCR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. The DCR as assessed by BICR per RECIST 1.1 is presented. Protocol-specified final analysis for this secondary outcome measure was performed with an analysis data cut-off date of Jul-26-2021.

Time frame:
Up to approximately 25 months
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR)
Percentage of ParticipantsPembrolizumab + LenvatinibPembrolizumab + Placebo
Disease Control Rate (DCR)66.9 (60.7 to 72.8)56.2 (49.7 to 62.5)
SecondaryChange From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS) (Item 29) and Quality of Life (QOL) (Item 30) Combined Score

The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions regarding GHS ("How would you rate your overall health during the past week?") and QOL ("How would you rate your overall quality of life during the past week?") were scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores were standardized, so that scores range from 0 to 100. The change from baseline in GHS (EORTC QLQ-C30 Item 29) and QOL (EORTC QLQ-C30 Item 30) combined score is presented. A higher score indicates a better outcome. Final analysis for this secondary outcome measure was performed with an analysis data cut-off date of Jul-26-2021, as specified in the Supplemental Statistical Analysis Plan (sSAP).

Time frame:
Baseline and Week 11
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS) (Item 29) and Quality of Life (QOL) (Item 30) Combined Score
Scores on a scalePembrolizumab + LenvatinibPembrolizumab + Placebo
Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS) (Item 29) and Quality of Life (QOL) (Item 30) Combined Score0.73 (-2.63 to 4.09)3.79 (0.47 to 7.12)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · cLDA model · p = 0.182 (Two-sided p-value based on log rank test stratified on chemotherapy ineligibility, PD-L1 CPS, and ECOG PS.) · Difference in least squares means: -3.07 · 95% CI -7.57 to 1.44Based on a constrained longitudinal data analysis (cLDA) model with the PRO scores as the response variable with covariates for treatment by study visit interaction, and stratification factors by chemotherapy ineligibility, PD-L1 CPS, and ECOG PS.
SecondaryTime to True Deterioration (TTD) Based on Change From Baseline in EORTC QLQ-C30 GHS (Item 29) and QOL (Item 30) Combined Score

TTD was defined as the time from baseline to the first onset of a ≥10-point negative change (decrease) from baseline in GHS (EORTC QLQ-C30 Item 29) \& QOL (EORTC QLQ-C30 Item 30) combined score. The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions regarding GHS ("How would you rate your overall health during the past week?") and QOL ("How would you rate your overall quality of life during the past week?") were scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores were standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from baseline in GHS and QOL combined score, is presented. A longer TTD indicates a better outcome. Final analysis for this secondary outcome measure was performed with an analysis data cut-off date of Jul-26-2021, as specified in the sSAP.

Time frame:
Baseline and up to approximately 25 months
Reported as:
Median · Months
Time to True Deterioration (TTD) Based on Change From Baseline in EORTC QLQ-C30 GHS (Item 29) and QOL (Item 30) Combined Score
MonthsPembrolizumab + LenvatinibPembrolizumab + Placebo
Time to True Deterioration (TTD) Based on Change From Baseline in EORTC QLQ-C30 GHS (Item 29) and QOL (Item 30) Combined Score3.4 (2.1 to 4.3)7.6 (4.2 to NA)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · Log Rank · p = 0.0005 (Two-sided p-value based on log rank test stratified on chemotherapy ineligibility, PD-L1 CPS, and ECOG PS.) · Hazard ratio (hr): 1.64 · 95% CI 1.24 to 2.16Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by chemotherapy ineligibility, PD-L1 CPS, and ECOG PS.
SecondaryNumber of Participants Who Experience an AE

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE is presented. Final analysis for this secondary outcome measure was performed with an analysis data cut-off date of Jul-26-2021.

Time frame:
Up to approximately 25 months
Reported as:
Count of participants · Participants
Number of Participants Who Experience an AE
ParticipantsPembrolizumab + LenvatinibPembrolizumab + Placebo
Number of Participants Who Experience an AE234235
SecondaryNumber of Participants Who Discontinue Study Treatment Due to an AE

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE is presented. Final analysis for this secondary outcome measure was performed with an analysis data cut-off date of Jul-26-2021.

Time frame:
Up to approximately 25 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinue Study Treatment Due to an AE
ParticipantsPembrolizumab + LenvatinibPembrolizumab + Placebo
Number of Participants Who Discontinue Study Treatment Due to an AE8344

Adverse events

Collected over Up to approximately 52 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenvatinib + Pembrolizumab First Course178/251 (70.9%)155/247 (62.8%)238/247 (96.4%)
Placebo + Pembrolizumab First Course175/254 (68.9%)116/254 (45.7%)236/254 (92.9%)
Lenvatinib + Pembrolizumab → Pembrolizumab Second Course0/2 (0%)0/2 (0%)1/2 (50%)
Placebo + Pembrolizumab → Pembrolizumab Second Course0/5 (0%)0/5 (0%)5/5 (100%)
Most frequent serious events
Showing 10 of 207
Most frequent serious events
EventLenvatinib + Pembrolizumab First CoursePlacebo + Pembrolizumab First CourseLenvatinib + Pembrolizumab → Pembrolizumab Second CoursePlacebo + Pembrolizumab → Pembrolizumab Second Course
PneumoniaInfections and infestations14/2475/2540/20/5
Urinary tract infectionInfections and infestations9/24714/2540/20/5
Acute kidney injuryRenal and urinary disorders12/2475/2540/20/5
DeathGeneral disorders7/2473/2540/20/5
HaematuriaRenal and urinary disorders6/2475/2540/20/5
AnaemiaBlood and lymphatic system disorders3/2476/2540/20/5
Cardiac failureCardiac disorders5/2471/2540/20/5
COVID-19 pneumoniaInfections and infestations5/2472/2540/20/5
PneumonitisRespiratory, thoracic and mediastinal disorders5/2473/2540/20/5
Cardiac arrestCardiac disorders4/2470/2540/20/5
Most frequent other events
Showing 10 of 57
Most frequent other events
EventLenvatinib + Pembrolizumab First CoursePlacebo + Pembrolizumab First CourseLenvatinib + Pembrolizumab → Pembrolizumab Second CoursePlacebo + Pembrolizumab → Pembrolizumab Second Course
HaemorrhoidsGastrointestinal disorders6/2472/2541/20/5
ProteinuriaRenal and urinary disorders101/24771/2540/20/5
HypertensionVascular disorders99/24723/2540/20/5
Urinary tract infectionInfections and infestations54/24746/2540/22/5
Blood creatine phosphokinase increasedInvestigations4/24711/2540/22/5
HypothyroidismEndocrine disorders98/24727/2540/20/5
Decreased appetiteMetabolism and nutrition disorders68/24743/2540/20/5
DiarrhoeaGastrointestinal disorders65/24751/2540/20/5
AnaemiaBlood and lymphatic system disorders48/24764/2540/20/5
NauseaGastrointestinal disorders52/24744/2540/20/5

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pembrolizumab + LenvatinibPembrolizumab + PlaceboTotal
Mean72.3 ± 9.371.9 ± 8.572.1 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab + LenvatinibPembrolizumab + PlaceboTotal
Female7759136
Male174195369
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab + LenvatinibPembrolizumab + PlaceboTotal
Hispanic or Latino171027
Not Hispanic or Latino213218431
Unknown or Not Reported212647
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab + LenvatinibPembrolizumab + PlaceboTotal
American Indian or Alaska Native011
Asian7879157
Native Hawaiian or Other Pacific Islander000
Black or African American000
White164157321
More than one race011
Unknown or Not Reported91625
Chemotherapy Ineligibility, Combined Positive Score (CPS), Eastern Cooperative Oncology Group (ECOG)
Chemotherapy Ineligibility, Combined Positive Score (CPS), Eastern Cooperative Oncology Group (ECOG)(Participants)Pembrolizumab + LenvatinibPembrolizumab + PlaceboTotal
Ineligible for any platinum agents CPS ≥10 ECOG 28384167
Ineligible for any platinum agents CPS <10 ECOG 2118120238
Cisplatin-ineligible CPS ≥10 ECOG 28816
Cisplatin-ineligible CPS ≥10 ECOG 0 or 1424284
08

Study locations

194 sites
  • Banner MD Anderson Cancer Center ( Site 0016)
    Gilbert, Arizona 85234, United States
  • Community Cancer Institute ( Site 0777)
    Clovis, California 93611, United States
  • University of California Irvine Medical Center ( Site 0078)
    Orange, California 92868, United States
  • John Wayne Cancer Institute ( Site 0017)
    Santa Monica, California 90404, United States
  • Northwest Georgia Oncology Centers PC ( Site 0707)
    Marietta, Georgia 30060, United States
  • University of Chicago ( Site 0039)
    Chicago, Illinois 60637, United States
  • Joliet Oncology Hematology ( Site 0091)
    Joliet, Illinois 60436, United States
  • Quincy Medical Group ( Site 0022)
    Quincy, Illinois 62301, United States
  • New England Cancer Specialists ( Site 0047)
    Scarborough, Maine 04074, United States
  • Karmanos Cancer Institute ( Site 0712)
    Detroit, Michigan 48201, United States
  • Mercy Hospital Saint Louis - David C. Pratt Cancer Center ( Site 0095)
    St Louis, Missouri 63141, United States
  • Comprehensive Cancer Centers of Nevada ( Site 0005)
    Las Vegas, Nevada 89169, United States
  • St. Peter's Hospital Cancer Care Center ( Site 0042)
    Albany, New York 12208, United States
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0002)
    New York, New York 10016, United States
  • Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0774)
    Tulsa, Oklahoma 74146, United States
  • Thomas Jefferson University Hospital ( Site 0051)
    Philadelphia, Pennsylvania 19107, United States
  • Medical University of South Carolina-Hollings Cancer Center ( Site 0029)
    Charleston, South Carolina 29425, United States
  • Baylor Scott & White Medical Center - Temple ( Site 0706)
    Temple, Texas 76508, United States
  • Virginia Cancer Institute ( Site 0099)
    Richmond, Virginia 23230, United States
  • Seattle Cancer Care Alliance ( Site 0003)
    Seattle, Washington 98109, United States
  • Cancer Care Northwest ( Site 0009)
    Spokane, Washington 99218, United States
  • Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 0577)
    Berazategui, Buenos Aires B1884BBF, Argentina
  • Centro de Urología CDU ( Site 0590)
    Buenos Aires, Buenos Aires F.D. C1120AAT, Argentina
  • Instituto Medico Alexander Fleming ( Site 0578)
    Buenos Aires, Buenos Aires F.D. C1426ANZ, Argentina
  • Centro de Investigaciones Clinicas - Clinica Viedma ( Site 0585)
    Viedma, Río Negro Province R8500ACE, Argentina
  • Centro Oncológico de Rosario ( Site 0584)
    Rosario, Santa Fe Province S2000KZE, Argentina
  • Instituto de Investigaciones Metabolicas ( Site 0589)
    Buenos Aires, C1012AAR, Argentina
  • Centro Medico Dra De Salvo ( Site 0593)
    Buenos Aires, C1426ANZ, Argentina
  • CEMAIC ( Site 0581)
    Córdoba, X5008HHW, Argentina
  • Centro Oncologico de Integracion Regional. COIR ( Site 0576)
    Mendoza, M5500AYB, Argentina
  • Macquarie University ( Site 0151)
    North Ryde, New South Wales 2109, Australia
  • Mater Misericordiae Ltd ( Site 0158)
    South Brisbane, Queensland 4101, Australia
  • Monash Health ( Site 0160)
    Clayton, Victoria 3168, Australia
  • Peninsula Health Frankston Hospital ( Site 0153)
    Frankston, Victoria 3199, Australia
  • Austin Health-Austin Hospital ( Site 0154)
    Heidelberg, Victoria 3084, Australia
  • Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0101)
    Hamilton, Ontario L8V 5C2, Canada
  • Lakeridge Health ( Site 0103)
    Oshawa, Ontario L1G 2B9, Canada
  • Sunnybrook Research Institute ( Site 0106)
    Toronto, Ontario M4N 3M5, Canada
  • CHUQ-Univ Laval-Hotel Dieu de Quebec ( Site 0104)
    Québec, Quebec G1R 2J6, Canada
  • CIUSSS de l Estrie Centre Hospitalier Universitaire de Sherbrooke ( Site 0102)
    Sherbrooke, Quebec J1H5N4, Canada
  • Peking University First Hospital ( Site 0726)
    Beijing, Beijing Municipality 100034, China
  • Fifth Medical Center of CPLA General Hospital ( Site 0732)
    Beijing, Beijing Municipality 100071, China
  • Peking University Third Hospital ( Site 0727)
    Beijing, Beijing Municipality 100089, China
  • Chongqing Cancer Hospital ( Site 0741)
    Chongging, Chongqing Municipality 400030, China
  • The First Affiliated Hospital of Xiamen University ( Site 0743)
    Xiamen, Fujian 361003, China
  • Sun Yat-Sen University Cancer Center ( Site 0752)
    Guangdong, Guangdong 510060, China
  • The First Affiliated Hospital of Guangzhou Medical University ( Site 0749)
    Guangzhou, Guangdong 510230, China
  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ( Site 0746)
    Guangzhou, Guangdong 510289, China
  • Harbin Medical University Cancer Hospital ( Site 0750)
    Harbin, Heilongjiang 150081, China
  • Hubei Cancer Hospital ( Site 0744)
    Wuhan, Hubei 430079, China
  • Hunan Cancer Hospital ( Site 0745)
    Changsha, Hunan 410013, China
  • Nanjing Drum Tower Hospital ( Site 0737)
    Nanjing, Jiangsu 210008, China
  • Fudan University Shanghai Cancer Center ( Site 0721)
    Shanghai, Shanghai Municipality 200032, China
  • Zhongshan Hospital Fudan University ( Site 0725)
    Shanghai, Shanghai Municipality 200032, China
  • The First Affiliated Hospital of Xi an Jiaotong University ( Site 0738)
    Xian, Shanxi 710061, China
  • Cancer Hospital Affiliated to Xinjiang Medical University ( Site 0751)
    Ürümqi, Xinjiang 830011, China
  • Second Affiliated Hospital, Zhejiang University ( Site 0734)
    Hangzhou, Zhejiang 310009, China
  • Zhejiang Provincial People's Hospital ( Site 0735)
    Hangzhou, Zhejiang 310014, China
  • Rigshospitalet ( Site 0680)
    Copenhagen, Capital Region 2100, Denmark
  • Herlev Hospital ( Site 0681)
    Herlev, Capital Region 2730, Denmark
  • Aarhus Universitets hospital ( Site 0683)
    Aarhus N, Central Jutland 8200, Denmark
  • Aalborg Universitets Hospital ( Site 0684)
    Aalborg, North Denmark 9000, Denmark
  • Odense Universitetshospital ( Site 0682)
    Odense, Region Syddanmark 5000, Denmark
  • CHU Poitiers ( Site 0253)
    Poitiers, Ain 86021, France
  • Institut de Cancerologie Strasbourg Europe ( Site 0232)
    Strasbourg, Alsace 67033, France
  • Hopital de la Timone ( Site 0246)
    Marseille, Bouches-du-Rhone 13005, France
  • CHIC Quimper ( Site 0245)
    Quimper, Finistere 29107, France
  • CHU de Bordeaux- Hopital Saint Andre ( Site 0235)
    Bordeaux, Gironde 33075, France
  • Clinique Pasteur ( Site 0252)
    Tolouse, Haute-Garonne 31076, France
  • Centre de Cancerologie du Grand Montpellier ( Site 0249)
    Montpellier, Languedoc-Roussillon 34070, France
  • Centre Rene Gauducheau ICO ( Site 0250)
    Saint-Herblain, Loire-Atlantique 44805, France
  • Institut de Cancerologie de l Ouest Site Paul Papin ( Site 0236)
    Angers, Maine-et-Loire 49055, France
  • Centre D Oncologie de Gentilly ( Site 0240)
    Nancy, Meurthe-et-Moselle 54100, France
  • Centre Hospitalier de la Cote Basque ( Site 0239)
    Bayonne, Pyrenees-Atlantiques 64109, France
  • Centre Leon Berard ( Site 0244)
    Lyon, Rhone 69373, France
  • Institut Gustave Roussy ( Site 0243)
    Villejuif, Val-de-Marne 94805, France
  • CHD Vendee-onco-hematologie ( Site 0251)
    La Roche-sur-Yon, Vendee 85925, France
  • Institut Curie ( Site 0237)
    Paris, 75005, France
  • Klinikum der Eberhard-Karls-Universitaet Tuebingen ( Site 0271)
    Tübingen, Baden-Wurttemberg 72076, Germany
  • Universitaetsklinikum Giessen und Marburg GmbH ( Site 0284)
    Marburg, Hesse 35032, Germany
  • Universitaetsmedizin Goettingen ( Site 0281)
    Göttingen, Lower Saxony 37075, Germany
  • Helios Kliniken Schwerin GmbH ( Site 0278)
    Schwerin, Mecklenburg-Vorpommern 19049, Germany
  • Universitaetsklinikum Essen ( Site 0274)
    Essen, North Rhine-Westphalia 45147, Germany
  • Staedtisches Krankenhaus Kiel GmbH ( Site 0285)
    Kiel, Schleswig-Holstein 24116, Germany
  • Universitaetsklinikum Schleswig-Holstein-Campus Lubeck ( Site 0277)
    Lübeck, Schleswig-Holstein 23538, Germany
  • Universitaetsklinikum Hamburg-Eppendorf ( Site 0282)
    Hamburg, 20246, Germany
  • Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Okta-Klinikai Onkológiai és Sugárterápiás Ce
    Miskolc, Borsod-Abauj Zemplen county 3526, Hungary
  • Bacs-Kiskun Megyei Korhaz ( Site 0510)
    Kecskemét, Bács-Kiskun county 6000, Hungary
  • Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 0507)
    Szolnok, Jász-Nagykun-Szolnok 5000, Hungary
  • Markusovszky Egyetemi Oktatokorhaz ( Site 0502)
    Szombathely, Vas County 9400, Hungary
  • Bajcsy Zsilinszki Korhaz es Rendelointezet ( Site 0509)
    Budapest, 1106, Hungary
  • Orszagos Onkologiai Intezet ( Site 0503)
    Budapest, 1122, Hungary
  • Uzsoki Utcai Korhaz ( Site 0508)
    Budapest, 1145, Hungary
  • Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 0504)
    Kaposvár, 7400, Hungary
  • Ha Emek Medical Center ( Site 0560)
    Afula, 1834111, Israel
  • Assuta Ashdod Public ( Site 0562)
    Ashdod, 7747629, Israel
  • Rambam Medical Center ( Site 0552)
    Haifa, 3109601, Israel
  • Shaare Zedek Medical Center ( Site 0559)
    Jerusalem, 9103102, Israel
  • Hadassah Ein Kerem Medical Center ( Site 0558)
    Jerusalem, 9112001, Israel
  • Meir Medical Center ( Site 0554)
    Kfar Saba, 4428164, Israel

Showing the first 100 of 194 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Matsubara N, de Wit R, Balar AV, Siefker-Radtke AO, Zolnierek J, Csoszi T, Shin SJ, Park SH, Atduev V, Gumus M, Su YL, Karaca SB, Cutuli HJ, Sendur MAN, Shen L, O'Hara K, Okpara CE, Franco S, Moreno BH, Grivas P, Loriot Y. Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial. Eur Urol. 2024 Mar;85(3):229-238. doi: 10.1016/j.eururo.2023.08.012. Epub 2023 Sep 29. PubMed 37778952 ↗
  • Taylor MH, Schmidt EV, Dutcus C, Pinheiro EM, Funahashi Y, Lubiniecki G, Rasco D. The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. Future Oncol. 2021 Feb;17(6):637-648. doi: 10.2217/fon-2020-0937. Epub 2020 Dec 10. PubMed 33300372 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Jul 2021, 26 months.

Results were first posted in Oct 2023, 2 years 3 months after primary completion.

Of 28 phase 3 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 111. This study's 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2019
First posted
Apr 1, 2019
StartActual
May 6, 2019
Primary completionActual
Jul 26, 2021
CompletionActual
May 20, 2024
Results first posted
Oct 31, 2023
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03898180
Collaborators
Eisai Inc.
Responsible party
Sponsor
First posted
Apr 1, 2019
Start date
May 6, 2019
Primary completion
Jul 26, 2021
Completion
May 20, 2024
Results posted
Oct 31, 2023
Last update
Feb 5, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion